If you suffer from rheumatoid arthritis (RA), Dr. Salah Ahmed’s research project may be just your cup of (green) tea! Dr. Ahmed’s 2014 Innovative Research Grant project, “Mechanism of Mcl-1 regulation in RA by EGCG”, looked at the effects of an anti-inflammatory molecule found in green tea (epigallocatechin-3-gallate or EGCG) on a protein (Mcl-1) found in RA joints.
Major depression is not uncommon in people with rheumatoid arthritis (RA) – different studies have pegged the number at between 17 percent and 40 percent – but the drugs used to treat RA do little to alleviate depression, according to a systematic review presented at the 2017 British Society for Rheumatology annual conference in Birmingham, United Kingdom.
Continue reading Arthritis Drugs Help Physical Symptoms More Than Disease-Related Depression
What a wonderful weekend! The 10th annual National Gathering Conference was held last weekend June 9-11 in Kansas City and what a weekend it was! This year’s conference was particularly special – we celebrated 10 amazing years of this wonderful Gathering which was reflected in the conference theme “10 Years & Growing,” and throughout the conference.
The Gathering was created for adults living with arthritis and rheumatic diseases to gather together and learn from healthcare and patient experts how to live their best life. We all know living with arthritis is difficult, but at the Gathering we learn together how to combat life’s daily challenges.
Continue reading Highlights from the 10th Annual National Gathering Conference
What if injured joints could heal themselves before they develop osteoarthritis (OA)? Dr. James Martin’s current 3-year Arthritis Foundation-funded project, “Engineering Endogenous Cartilage Repair,” is trying to do just that- find ways to help joints heal before developing OA.
Dr. Martin and his team use special goats that have defects in areas of the thigh bones and cartilage, just above the knee. This closely mimics knee injuries that are seen in humans. The defects are surgically repaired with a hydrogel matrix that contains two important ingredients: repair cell attractant and growth factor. The repair cell attractant causes repair cells, called chondrogenic progenitor cells (CPCs), to migrate into the hydrogel. CPCs naturally occur in the cartilage. The growth factor, which is time-released over 10 days, causes the CPCs in the hydrogel to multiply and repair the injury with new cartilage.
Continue reading Researchers on the Path to a Cure – Spotlight on Dr. James Martin
The Food and Drug Administration (FDA) recently approved the biologic drug sarilumab (Kevzara) for the treatment of rheumatoid arthritis (RA). Sarilumab blocks a protein called interleukin-6 (IL-6), which plays a key role in many inflammatory diseases, including RA. It’s the second IL-6 inhibitor to receive FDA approval for RA; the other, tocilizumab (Actemra), got the nod in 2010.
Continue reading FDA OKs a New Biologic for RA
Trillions of bacteria live in or on your body. There are actually as many bacteria in your body as cells in your body. Fortunately, for most of us, most bacteria that live within us are helpful, not harmful. We call these bacteria commensal bacteria. Dr. Martin Kriegel and his team have been studying these bacteria, and more specifically, a protein that humans and bacteria produce, called Ro60, that plays a role in the development of lupus.
Today, the president released the administration’s official budget request for fiscal year (FY) 2018, which would make deep cuts to health programs across health agencies and would have severe implications for Medicaid and other programs that deliver vital health care services to people with arthritis. While the Arthritis Foundation agrees that health care reform is necessary and our country needs to make important spending decisions, it should not be at the expense of people with arthritis, which now affects one in four Americans and the prevalence is growing.
The U.S. Food and Drug Administration (FDA) has approved Renflexis (infliximab-abda), a biosimilar to Remicade (infliximab), making it the fourth biosimilar approved to treat inflammatory types of arthritis.
Renflexis is the second approved biosimilar to Remicade. The first one, Inflectra (infliximab-dyyb), was approved in April 2016. This is the first time the FDA has approved two biosimilars for one original, “reference” medication.
Continue reading FDA Approves Second Remicade biosimilar
More than 50 million Americans have arthritis – that’s one in four people. It’s currently the nation’s number one cause of disability.
But this month—with your help— we’re fighting back with the #FightFor50 campaign! To participate, we are asking that you share your story — tell us about your personal fight with arthritis, or tell us about a person you are fighting for, whether it’s parent, grandparent, sibling, partner or a friend.
Continue reading Share Your Story! Help Us Raise Awareness this Arthritis Awareness Month
Early in life while mowing lawns, growing and selling tomatoes and managing a neighborhood McDonald’s restaurant as a junior in high school, Kevin Mandrell always knew he had a natural knack for business. He was surrounded by strong business leaders and felt drawn from an early age to dive into business on his own.
Continue reading Creating a Legacy to Conquer Arthritis